HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 4 (2007), Issue 1 (January)

1. Evidence for BAG3 modulation of HIV-1 gene transcription.
   J Cell Physiol, 210(3): 676-83. [Abstract] [Full-text]
2. Correlates of anxiety and depression among HIV test-seekers at a Voluntary Counseling and Testing facility in Pune, India.
   Qual Life Res, 16(1): 41-52. [Abstract] [Full-text]
3. Screening for acute HIV infection: lessons learned.
   Clin Infect Dis, 44(3): 459-61. [Abstract] [Full-text]
4. Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection.
   Clin Infect Dis, 44(3): 456-8. [Abstract] [Full-text]
5. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
   Clin Infect Dis, 44(3): 447-52. [Abstract] [Full-text]
6. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
   Clin Infect Dis, 44(3): 441-6. [Abstract] [Full-text]
7. Case-control study of shigellosis in San Francisco: the role of sexual transmission and HIV infection.
   Clin Infect Dis, 44(3): 327-34. [Abstract] [Full-text]
8. Multiple organ failure during primary HIV infection.
   Clin Infect Dis, 44(3): e28-9. [Abstract] [Full-text]
9. Selective defect in plasmacyoid dendritic cell function in a patient with AIDS-associated atypical genital herpes simplex vegetans treated with imiquimod.
   Clin Infect Dis, 44(3): e25-7. [Abstract] [Full-text]
10. HIV-1 Tat interaction with Dicer: requirement for RNA.
    Retrovirology, 3: 95. [Abstract] [Full-text]
11. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.
    J Infect Dis, 195(3): 425-31. [Abstract] [Full-text]
12. Rapid, real-time detection of acute HIV infection in patients in Africa.
    J Infect Dis, 195(3): 416-24. [Abstract] [Full-text]
13. Reconstitution of herpes simplex virus-specific T cell immunity in HIV-infected patients receiving highly active antiretroviral therapy.
    J Infect Dis, 195(3): 410-5. [Abstract] [Full-text]
14. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.
    J Infect Dis, 195(3): 399-409. [Abstract] [Full-text]
15. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection.
    J Infect Dis, 195(3): 392-8. [Abstract] [Full-text]
16. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    J Infect Dis, 195(3): 387-91. [Abstract] [Full-text]
17. Characteristics and HIV risk behaviors of homeless, substance-using men who have sex with men.
    Addict Behav, 32(3): 647-54. [Abstract] [Full-text]
18. The impact of managed care on access to highly active antiretroviral therapy and on outcomes among Medicaid beneficiaries with AIDS.
    Med Care Res Rev, 64(1): 66-82. [Abstract] [Full-text]
19. Response to antiretroviral therapy after a single, peripartum dose of nevirapine.
    N Engl J Med, 356(2): 135-47. [Abstract] [Full-text]
20. Using theatrical presentations as a means of disseminating knowledge of HIV/AIDS risk factors to migrant farmworkers: an evaluation of the effectiveness of the Infórmate program.
    J Immigr Minor Health, 9(2): 147-56. [Abstract] [Full-text]
21. Analysis of amino acids in the beta7-beta8 loop of human immunodeficiency virus type 1 reverse transcriptase for their role in virus replication.
    J Mol Biol, 365(5): 1368-78. [Abstract] [Full-text]
22. Identification of the LEDGF/p75 binding site in HIV-1 integrase.
    J Mol Biol, 365(5): 1480-92. [Abstract] [Full-text]
23. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10.
    J Mol Biol, 365(5): 1533-44. [Abstract] [Full-text]
24. Diffuse cutaneous leishmaniasis in an HIV-positive patient in western Africa.
    Australas J Dermatol, 48(1): 32-4. [Abstract] [Full-text]
25. The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages.
    Virus Res, 123(2): 178-89. [Abstract] [Full-text]
26. Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1.
    Virus Res, 123(2): 161-9. [Abstract] [Full-text]
27. In vitro cell fusion between CD4(+) and HIV-1 Env(+) T cells generates a diversity of syncytia varying in total number, size and cellular content.
    Virus Res, 123(2): 138-46. [Abstract] [Full-text]
28. A randomized control trial of Internet-delivered HIV prevention targeting rural MSM.
    Health Educ Res, 22(1): 120-7. [Abstract] [Full-text]
29. Comparing the magnitude of discriminatory attitudes toward people living with HIV/AIDS and toward people with mental illness in the Hong Kong general population.
    Health Educ Res, 22(1): 139-52. [Abstract] [Full-text]
30. HIV-1 coreceptors CCR5 and CXCR4 both mediate neuronal cell death but CCR5 paradoxically can also contribute to protection.
    Cell Death Differ, 14(2): 296-305. [Abstract] [Full-text]
31. Written medicines information for South African HIV/AIDS patients: does it enhance understanding of co-trimoxazole therapy?
    Health Educ Res, 22(1): 37-48. [Abstract] [Full-text]
32. Atypical cutaneous manifestation of HSV-2 with Candida albicans co-infection in a patient with HIV-1.
    J Infect, 54(2): e55-7. [Abstract] [Full-text]
33. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    J Infect, 54(2): 159-66. [Abstract] [Full-text]
34. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients.
    J Infect, 54(2): 173-9. [Abstract] [Full-text]
35. HSV-2- and HIV-1- permissive cell lines co-infected by HSV-2 and HIV-1 co-replicate HSV-2 and HIV-1 without production of HSV-2/HIV-1 pseudotype particles.
    Virol J, 4: 2. [Abstract] [Full-text]
36. Experimental approaches to the study of HIV-1 latency.
    Nat Rev Microbiol, 5(2): 95-106. [Abstract] [Full-text]
37. Short-term energy restriction reduces resting energy expenditure in patients with HIV lipodystrophy and hypermetabolism.
    Metabolism, 56(2): 289-95. [Abstract] [Full-text]
38. Is HIV-1 evolving to a less virulent form in humans?
    Nat Rev Microbiol, 5(2): 141-51. [Abstract] [Full-text]
39. Analysis of HIV-1-X4 fusion with immature dendritic cells identifies a specific restriction that is independent of CXCR4 levels.
    J Invest Dermatol, 127(2): 319-23. [Abstract] [Full-text]
40. Is the HIV burden in India being overestimated?
    BMC Public Health, 6: 308. [Abstract] [Full-text]
41. The antiretrovirals in pregnancy registry: a fifteenth anniversary celebration.
    Obstet Gynecol Surv, 62(2): 137-48. [Abstract] [Full-text]
42. SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells.
    Retrovirology, 4: 2. [Abstract] [Full-text]
43. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
    BMJ, 334(7585): 136. [Abstract] [Full-text]
44. Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag.
    Vaccine, 25(9): 1634-46. [Abstract] [Full-text]
45. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial.
    Arch Intern Med, 167(2): 148-54. [Abstract] [Full-text]
46. Temporal trends in the incidence of HIV infection in antenatal clinic attendees in Addis Ababa, Ethiopia, 1995-2003.
    J Intern Med, 261(2): 132-7. [Abstract] [Full-text]
47. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results.
    J Intern Med, 261(2): 123-31. [Abstract] [Full-text]
48. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.
    Clin Infect Dis, 44(4): 607-14. [Abstract] [Full-text]
49. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy.
    Clin Infect Dis, 44(4): 599-604. [Abstract] [Full-text]
50. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
    Clin Infect Dis, 44(4): 591-5. [Abstract] [Full-text]
51. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
    Clin Infect Dis, 44(4): 584-90. [Abstract] [Full-text]
52. Factors associated with seronegative chronic hepatitis C virus infection in HIV infection.
    Clin Infect Dis, 44(4): 577-83. [Abstract] [Full-text]
53. Promises and challenges of faith-based AIDS care and support in Mozambique.
    Am J Public Health, 97(2): 362-6. [Abstract] [Full-text]
54. Vaccine-based, long-term, stable control of simian/human immunodeficiency virus 89.6PD replication in rhesus macaques.
    J Gen Virol, 88: 652-9. [Abstract] [Full-text]
55. Influence of interleukin-15 on CD8+ natural killer cells in human immunodeficiency virus type 1-infected chimpanzees.
    J Gen Virol, 88: 641-51. [Abstract] [Full-text]
56. C/EBPbeta regulates human immunodeficiency virus 1 gene expression through its association with cdk9.
    J Gen Virol, 88: 631-40. [Abstract] [Full-text]
57. Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi's sarcoma among men who have sex with men in a European multicentre study.
    Int J Cancer, 120(5): 1129-35. [Abstract] [Full-text]
58. Recommendations in pediatric antiretroviral therapy.
    Expert Opin Pharmacother, 8(2): 155-66. [Abstract] [Full-text]
59. Care and treatment of HIV-infected children in Africa: issues and challenges at the district hospital level.
    Pediatr Infect Dis J, 26(2): 163-73. [Abstract] [Full-text]
60. Visual loss secondary to acquired immunodeficiency virus-related progressive multifocal leukoencephalopathy demonstrating clinical improvement with highly active antiretroviral therapy.
    Optometry, 78(2): 63-70. [Abstract] [Full-text]
61. Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals.
    PLoS Genet, 3(1): e19. [Abstract] [Full-text]
62. Neighborhood and HIV infection among IDU: place of residence independently predicts HIV infection among a cohort of injection drug users.
    Health Place, 13(2): 432-9. [Abstract] [Full-text]
63. Placing the dynamics of syringe exchange programs in the United States.
    Health Place, 13(2): 417-31. [Abstract] [Full-text]
64. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa.
    Neurology, 68(5): 350-5. [Abstract] [Full-text]
65. Gelsolin segment 5 inhibits HIV-induced T-cell apoptosis via Vpr-binding to VDAC.
    FEBS Lett, 581(3): 535-40. [Abstract] [Full-text]
66. Can current national surveillance systems in England and Wales monitor sexual transmission of hepatitis C among HIV-infected men who have sex with men?
    BMC Public Health, 7: 7. [Abstract] [Full-text]
67. Ascaris-induced eosinophilic pneumonitis in an HIV-infected patient.
    J Clin Pathol, 60(2): 202-3. [Abstract] [Full-text]
68. Detection of minor drug-resistant populations by parallel allele-specific sequencing.
    Nat Methods, 4(2): 123-5. [Abstract] [Full-text]

© 2004-2010 HIV Research Today. All Rights Reserved.